The Prognostic Value of Residual Gensini Score on 1-Year Cardiac Mortality in Patients Undergoing Percutaneous Coronary Intervention
Abstract
Background: Percutaneous coronary intervention (PCI) is a cornerstone in the management of obstructive coronary artery disease. The Gensini score quantitatively assesses the severity and complexity of coronary lesions. The residual Gensini score (rGensini), measured after PCI, may offer superior prognostic information compared with the baseline score. This study aimed to investigate the association between rGensini and cardiac mortality.
Methods: In this study, all consecutive patients who registered for follow-up at the Afshar Hospital Health Promotion Center within 30 days after PCI were included. The primary outcome was cardiac mortality. Baseline characteristics, comorbidities (diabetes, hypertension, dyslipidemia, and prior cardiac history), smoking status, family history, coronary dominance pattern, and coronary calcification were recorded. Patients were stratified into four risk categories based on rGensini: zero-risk (0), low-risk (>0 to ≤11), moderate-risk (>11 to ≤37), and high-risk (>37). Survival analysis was performed using the Kaplan-Meier method, and independent predictors of cardiac mortality were identified using Cox proportional hazards regression.
Results: The study included 141 patients (85 men and 56 women) with a mean age of 60.67 years. The mean Gensini score decreased from 31.22 at baseline to 18.20 after PCI. Over a median follow-up time of 9 months, 10 cardiac deaths occurred. Kaplan-Meier curves demonstrated a significant gradation in survival probability across the strata. Multivariable Cox regression analysis identified rGensini category, age, coronary calcification, diabetes, and hypertension as independent predictors of cardiac mortality.
Conclusion: This hypothesis-generating study suggests that the rGensini score is a promising and independent predictor of cardiac mortality after PCI.
2. Teoh Z, Al-Lamee RK. COURAGE, ORBITA, and ISCHEMIA: Percutaneous Coronary Intervention for Stable Coronary Artery Disease. Interv Cardiol Clin. 2020 Oct;9(4):469-82.
3. Faisal AWK, Ali K, Sadiq Z, Asar ZU, Latif W, Iqbal M. The procedural success of primary angioplasty in a tertiary care center in Pakistan. Pak J Med Sci. 2024 Dec;40(11):2583-7.
4. Okutucu S, Cilingiroglu M, Feldman MD. Physiologic Assessment of Coronary Stenosis: Current Status and Future Directions. Curr Cardiol Rep. 2021 Jun 3;23(7):88.
5. Neglia D, Liga R, Caselli C, Carpeggiani C, Lorenzoni V, Sicari R, et al; EVINCI Study Investigators. Anatomical and functional coronary imaging to predict long-term outcome in patients with suspected coronary artery disease: the EVINCI-outcome study. Eur Heart J Cardiovasc Imaging. 2020 Oct 20;21(11):1273-82.
6. Karaçağlar E, Akgün AN, Müderrisoğlu IH, Haberal M. Coronary Angiography for Follow-up of Heart Transplant Recipients: Usefulness of the Gensini Score. Exp Clin Transplant. 2020 Jan;18 Suppl1:99-104.
7. Wang KY, Zheng YY, Wu TT, Ma YT, Xie X. Predictive Value of Gensini Score in the Long-Term Outcomes of Patients with Coronary Artery Disease Who Underwent PCI. Front Cardiovasc Med. 2022 Jan 24;8:778615.
8. Lee JM, Hwang D, Choi KH, Lee HJ, Song YB, Cho YK, et al. Prognostic Impact of Residual Anatomic Disease Burden After Functionally Complete Revascularization. Circ Cardiovasc Interv. 2020 Sep;13(9):e009232.
9. Simard T, Jung RG, Di Santo P, Harnett DT, Abdel-Razek O, Ramirez FD, et al. Modifiable Risk Factors and Residual Risk Following Coronary Revascularization: Insights from a Regionalized Dedicated Follow-Up Clinic. Mayo Clin Proc Innov Qual Outcomes. 2021 Dec 4;5(6):1138-52.
10. Horne BD, Atreja N, Venditto J, Wilson T, Muhlestein JB, St Clair JR, et al. Contemporary Predictors of Major Adverse Cardiovascular Events Following Percutaneous Coronary Intervention: A Nationally Representative US Sample. J Clin Med. 2024 May 11;13(10):2844.
11. Anlar GG, Anwardeen N, Al Ashmar S, Pedersen S, Elrayess MA, Zeidan A. Metabolomics Profiling of Stages of Coronary Artery Disease Progression. Metabolites. 2024 May 22;14(6):292.
12. Xu S, Ilyas I, Little PJ, Li H, Kamato D, Zheng X, et al. Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies. Pharmacol Rev. 2021 Jul;73(3):924-67.
13. Rampidis GP, Benetos G, Benz DC, Giannopoulos AA, Buechel RR. A guide for Gensini Score calculation. Atherosclerosis. 2019 Aug;287:181-3.
14. Ahmed TAN, Othman AAA, Demitry SR, Elmaghraby KM. Impact of residual coronary lesions on outcomes of myocardial infarction patients with multi-vessel disease. BMC Cardiovasc Disord. 2024 Jan 23;24(1):68.
15. Koskinas KC, Mach F, Räber L. Lipid-lowering therapy and percutaneous coronary interventions. EuroIntervention. 2021 Apr 20;16(17):1389-403.
16. Gaba P, Gersh BJ, Muller J, Narula J, Stone GW. Evolving concepts of the vulnerable atherosclerotic plaque and the vulnerable patient: implications for patient care and future research. Nat Rev Cardiol. 2023 Mar;20(3):181-96.
17. Zhao N, Yu X, Zhu X, Song Y, Gao F, Yu B, et al. Diabetes Mellitus to Accelerated Atherosclerosis: Shared Cellular and Molecular Mechanisms in Glucose and Lipid Metabolism. J Cardiovasc Transl Res. 2024 Feb;17(1):133-52.
18. He L, Zhang CL, Chen Q, Wang L, Huang Y. Endothelial shear stress signal transduction and atherogenesis: From mechanisms to therapeutics. Pharmacol Ther. 2022 Jul;235:108152.
19. Drake T, Landsteiner A, Langsetmo L, MacDonald R, Anthony M, Kalinowski C, et al. Newer Pharmacologic Treatments in Adults with Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians. Ann Intern Med. 2024 May;177(5):618-32.
20. Shah M, Najam O, Bhindi R, De Silva K. Calcium Modification Techniques in Complex Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2021 May;14(5):e009870.
| Files | ||
| Issue | Vol 20 No 4 (2025) | |
| Section | Original Article(s) | |
| Keywords | ||
| Percutaneous Coronary Intervention Residual Gensini Score Cardiac Mortality Prognosis Coronary Artery Disease Comorbidities | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |

